Mind + Muscle

technical minds + legal muscle


dig deep

Biosimilars Get Their Day in Court

  • 09.08.14
  • Jenna Greene
  • The National Law Journal

Paul A. Calvo, Ph.D. was quoted in this The National Law Journal article discussing the decision by The U.S. Court of Appeals for the Federal Circuit to review the regulatory path for creating generic versions of biologic drugs. On Wednesday, September 10th The Federal Circuit will hear a suit by Sandoz Inc., which wants to make a generic version of Amgen Inc.'s arthritis drug Enbrel.

Mr. Calvo predicts that Sandoz will face an uphill battle at the Federal Circuit because Congress set out such a detailed framework for biosimilar approval. But the Federal Circuit is not the only avenue for Sandoz according to Mr. Calvo who said "there's nothing barring them from seeking an inter partes review." According to Mr. Calvo only one thing is certain "the patents are going to be litigated. That's as certain as the sun coming up tomorrow."

To view the full article, please visit The National Law Journal's website.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.